(NASDAQ: ONC) Beigene's forecast annual revenue growth rate of 23.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Beigene's revenue in 2025 is $3,810,241,000.On average, 4 Wall Street analysts forecast ONC's revenue for 2025 to be $7,114,805,886,966, with the lowest ONC revenue forecast at $7,084,731,917,246, and the highest ONC revenue forecast at $7,152,685,187,388. On average, 4 Wall Street analysts forecast ONC's revenue for 2026 to be $8,535,428,794,831, with the lowest ONC revenue forecast at $7,814,487,329,550, and the highest ONC revenue forecast at $8,864,447,207,938.
In 2027, ONC is forecast to generate $10,092,724,069,952 in revenue, with the lowest revenue forecast at $8,567,134,308,970 and the highest revenue forecast at $11,082,015,746,011.